-
Henlius ACE2-Fc receptor fusion protein HLX71 Phase I clinical results are positive
Time of Update: 2022-04-26
It is reported that HLX71 is a self-developed recombinant human Angiotensin converting enzyme 2 (hACE2) fusion protein with IgG1 Fc at the C-terminus, which is intended for the treatment of novel coronavirus pneumonia (COVID-19) .
-
HUAMN BRAIN MAPPING: CBF as an alternative method for measuring rs-FC
Time of Update: 2022-04-23
CBF-based resting-state functional magnetic resonance imaging (rs-fMRI) can replace BOLD-based rs-fMRI to obtain reliable rs-FC when the total acquisition time exceeds 10 min .
-
225 industry standards are submitted for approval and publicity, including a variety of instruments and testing methods
Time of Update: 2022-03-07
JB/T 20203-2022 JB/T 20203-2022 Drug Solution Color Tester Drug Solution Color Tester This document specifies the model, requirements, test methods, inspection rules, signs, instructions for use, packaging, transportation and storage of color measuring instruments for pharmaceutical solutions .
-
Greek olive oil exports increase by 225% from 2002 to 2020
Time of Update: 2021-08-01
Greece Ya Newswire June 15 reported that the Greek Olive Oil Producers Association
-
HUMAN BRAIN MAPPING: FC and structural connection measurement based on EEG and DTI help to study the posture control mechanism of traumatic brain injury
Time of Update: 2021-07-30
Compared with HC, the EEG measurement results of TBI showed the changes in baseline and task modulation of NS, GE, and global graph theory measurement of the modularization of brain function networks .
-
225 rounds of exploration by Shanghai Offshore Oil Bureau to strengthen safety management
Time of Update: 2021-07-12
promote the implementation of the ship safety responsibility system, do a good job of risk assessment, check and fill safety loopholes, and strengthen the management and control of operating procedures. In response to problems
-
[Plastic] PE imports reduced in April, exports surged 225%
Time of Update: 2021-06-08
In terms of polyethylene trade in April 2021, general trade accounted for 83%, a decrease of about 25% from the previous month, and the import volume was about 1.
-
225 million US dollars introduced!
Time of Update: 2021-05-09
The Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China has announced that the IMG-020 injection declared by Chuangxiang Biotechnology has obtained
-
Blood: Fc-RIIA expression aggravates lupus nephritis and promotes plate plateboard resuscing
Time of Update: 2021-01-15
in a newly established mouse model based on plate activation of IC-Fc-RIIA mediated human SLE, bone marrow cell expression Fc-RIIA significantly aggravated lupus nephritis and accelerated mouse death.
-
FRET-Based Imaging of Rac and Cdc42 Activation During Fc-Receptor-Mediated Phagocytosis in Macrophages
Time of Update: 2020-11-22
This chapter describes FRET microscopy methods to image the distribution of GTP-bound Rac and Cdc42 during the well-defined morphological transitions of phagocytosis by macrophages.
-
225 pharmaceutical companies pay announcement (with list)
Time of Update: 2020-11-13
over the past two years, CEOs of large and small pharmaceutical companies have received big pay increases, with the median increase of about 50 percent from 2017, a leap that has outpaced the increase in pay for their employees.
-
Blood: Fc-RIIA expression can aggravate nephritis and plateroid intensification of SLE.
Time of Update: 2020-09-02
, in genetically modified mice, Fc?RIIA is expressed in bone marrow cells, significantly exacerbating lupus nephritis and accelerating death.
-
CAR-T Killer! FDA approved CD19 target new Fc optimized immune-enhanced antibody Monjuvi, the treatment of B-cell tumors is strong!
Time of Update: 2020-08-06
or refractable diffuse large B-cell lymphoma (r/r DLBCL) patients who are not suitable for an autonomous stem cell transplant (ASCT), including DLBCL derived from low-level lymphoma. based on Total Remission Rate (ORR) data, Monjuvi has received FDA
-
"Optimized Edition" Herceptin! FC optimized immune-enhanced antibody margetuximab treatment
Time of Update: 2020-07-17
!--webeditor: "page title" - - July 11, 2020 /PRNewswire/ -- Reding Pharmaceutical Partners MacroGenics recently announced the evaluation of HER2 target antibody margetuximab in conjunction with Mercaiton anti-PD-1 therapy Keytruda (Coreda, generic
-
CD19 Targets New Fc Optimized Immune Enhancement Monoantid Tafasitamab To Apply for Listing in the U.S.
Time of Update: 2020-06-17
Recently, MorphoSys announced that it had filed a patentasitamab (MOR208) biologics licensing application (BLA) with the U.S. Food and Drug Administration (FDA) to treat patients with recurrent or refractive diffuse large B-cell lymphoma (r/r DLBCL).
-
FC-optimized HER2 single-fight Margetuximab treats stomach cancer, receives FDA award for orphan drug
Time of Update: 2020-06-16
Photo Source: Margetuximab is currently in a Phase 2/3 clinical trial maHOGANY (NCT04082364) to evaluate its potential as a first-line therapy for patients with HER2-positive gastric cancer (GC) or gastroesophageal connectivity (GEJ) in combination with immunocheckpoint inhibitors, with/without chemotherapy.
-
Blood: Effect of human-derived Fc receptor non-binding anti-CD3 monoclonal antibodies in T-ALL
Time of Update: 2020-06-16
Although immunotherapy has greatly improved the treatment of B-ALL and other B-cell malignancies, they have not yet been applied to T-ALL.
-
of rheumatoid arthritis, better than CTLA-4-Fc fusion protein abatacept
Time of Update: 2020-06-16
At the 2020 European Rheumatology Alliance Annual Meeting (EULAR 2020), AbbVie announced the latest data from the third select-CHOICE clinical trial, which showed that its JAK1 inhibitor, RINVOQ (upadacitinib), reached a major end point of non
-
After receiving $100 million in financing, Rongchang Bio's fusion protein TACI-Fc treatment of lupus lupus gets FDA fast-track designation
Time of Update: 2020-05-29
RemeGen announced that the U.S. Food and Drug Administration (FDA) has granted fast-track designations for its new recombinant TACI-Fc fusion protein RC18 to treat systemic lupus erythematosus (SLE).
-
CAR-T Killer! CD19 target new Fc-optimized immuno-enhanced monotafasitamab EU entry review, the treatment of B cell tumor efficacy is strong!
Time of Update: 2020-05-28
May 25, 2020 / Biovalley BIOON/ -- MorphoSys and Incyte recently jointly announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) of Tafasitamab (MOR208), the MA A seeks
